ストックスクリーナーアプリを入手
0.246
3.42%
-0.0087
アフターアワーズ：
.23
-0.016
-6.50%
前日終値:
$0.2547
開ける：
$0.2597
24時間の取引高:
334.36K
Relative Volume:
0.17
時価総額：
$16.36M
収益：
-
当期純損益:
$-17.78M
株価収益率:
-0.4479
EPS:
-0.5492
ネットキャッシュフロー:
$-10.52M
1週間 パフォーマンス:
+8.32%
1か月 パフォーマンス:
-36.15%
6か月 パフォーマンス:
-57.20%
1年 パフォーマンス:
-85.78%
1日の値動き範囲:
$0.2405
$0.2621
1週間の範囲:
$0.2312
$0.2842
52週間の値動き範囲:
$0.2201
$1.70
Fibrobiologics Inc Stock (FBLG) Company Profile
Compare FBLG vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.246 | 16.94M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-12 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-24 | 開始されました | Maxim Group | Buy |
Fibrobiologics Inc (FBLG) 最新ニュース
Aug Drivers: Can Xenetic Biosciences Inc be recession proofTrade Performance Summary & Long-Term Safe Investment Plans - baoquankhu1.vn
FibroBiologics CEO Pete O’Heeron to Speak at A4LI's H-SPAN Summit on Longevity Science - Quiver Quantitative
Longevity policy summit taps FibroBiologics CEO for main stage talk - Stock Titan
Is FibroBiologics Inc. benefiting from interest rate changesJuly 2025 Trends & Technical Pattern Based Signals - mfd.ru
FibroBiologics Faces Nasdaq Delisting Review After Noncompliance - TipRanks
FibroBiologics Received Notice of Delisting - TradingView
FibroBiologics Secures Canadian Patent for Innovative Cachexia Treatment Using Fibroblast Cells - Quiver Quantitative
New fibroblast therapy targets cachexia, wasting in chronic disease - Stock Titan
FibroBiologics (NASDAQ:FBLG) Shares Down 1.6% – What’s Next? - Defense World
Market Recap: Whats the fair value of FibroBiologics Inc stockSell Signal & Reliable Trade Execution Plans - baoquankhu1.vn
Sell Signal: Will IVCA outperform its industry peersJuly 2025 Sentiment & Precise Swing Trade Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
FibroBiologics to Present at the DealFlow Discovery Conference - 富途牛牛
Biotech with 270+ patents meets investors at DealFlow Discovery - Stock Titan
Risk Recap: Is FibroBiologics Inc stock a smart retirement pickJuly 2025 Chart Watch & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Aug EndMonth: Why retail investors favor FibroBiologics Inc stockJuly 2025 Snapshot & Safe Swing Trade Setups - Bộ Nội Vụ
Levels Update: Why retail investors favor FibroBiologics Inc stock2025 AllTime Highs & Long-Term Safe Investment Ideas - Bộ Nội Vụ
How FibroBiologics Inc. stock benefits from strong dollarWeekly Trade Summary & Long-Term Growth Stock Strategies - Улправда
Why analysts remain bullish on FibroBiologics Inc. stockTrade Risk Summary & Consistent Profit Trading Strategies - Улправда
Will FibroBiologics Inc. stock remain a Wall Street favoriteWeekly Loss Report & Reliable Price Action Trade Plans - Улправда
Why FibroBiologics Inc. stock is a must watch in 2025July 2025 Breakouts & Verified Swing Trading Watchlists - Улправда
FibroBiologics faces Nasdaq delisting, plans reverse split - MSN
FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 1Q26 - Yahoo Finance
FibroBiologics to begin diabetic foot ulcer clinical trial in Q1 2026 - Investing.com Nigeria
Why FibroBiologics Inc. (SG0) stock attracts wealthy investorsStock Market Trends & Minimize Portfolio Damage with Warnings - ulpravda.ru
FibroBiologics CEO Issues Letter to Shareholders - markets.businessinsider.com
FibroBiologics to begin diabetic foot ulcer clinical trial in Q1 2026 By Investing.com - Investing.com South Africa
FibroBiologics (NASDAQ:FBLG) Given “Buy” Rating at D. Boral Capital - Defense World
How interest rate cuts could boost FibroBiologics Inc. stock2026 world cup usa national team round of 16 defensive leaders possession football expert forecast insights - Улправда
FibroBiologics (FBLG) Rating Maintained as "Buy" by D. Boral Cap - GuruFocus
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference - The Manila Times
FibroBiologics reports positive results for disc degeneration therapy By Investing.com - Investing.com Nigeria
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte Spheroid Therapy for Degenerative Disc Disease - marketscreener.com
FibroBiologics reports positive results for disc degeneration therapy - Investing.com
FibroBiologics Announces Positive Preclinical Results for a - GlobeNewswire
Fibrobiologics files IND for CYPS-317 to treat psoriasis - BioWorld MedTech
FibroBiologics Advances Psoriasis Therapy Pipeline Through FDA IND Filing For CYPS317 - Voice Of HealthCare
FibroBiologics (NASDAQ:FBLG) Given “Buy” Rating at HC Wainwright - Defense World
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), FibroBiologics, Inc. (FBLG) and Corcept Therapeutics (CORT) - The Globe and Mail
FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split - TipRanks
FibroBiologics receives Nasdaq delisting notice, requests hearing to appeal By Investing.com - Investing.com South Africa
FibroBiologics receives Nasdaq delisting notice, requests hearing to appeal - Investing.com
FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing - Investing.com Canada
FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing By Investing.com - Investing.com South Africa
FBLG: HC Wainwright & Co. Reiterates Buy Rating with Price Targe - GuruFocus
Fibrobiologics Inc (FBLG) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):